BioOutsource
BioOutsource, a leading international contract testing organisation (CTO), has consolidated its position as a leading expert in the biological analysis of biosimilar monoclonal antibodies for the biopharmaceutical industry. Strategic internal R&D investment has enabled the creation and launch of a wide range of off-the-shelf testing methodologies to support comparability, stability and lot release testing for biosimilars. As a result, the company has achieved excellent market penetration and sales growth this year and is now working in collaboration with many of the world’s leading biosimilar companies.
BioOutsource CEO Gerry MacKay commented: “Our extensive experience in developing and validating cell-based assays and strategic R&D investment has created a niche position for us within the industry, which enables BioOutsource to provide testing solutions that can significantly reduce the time and cost of biosimilar development programmes.
“We are continuing to invest and expand our testing capabilities in Glasgow, Scotland, and are significantly increasing commercial activities in the North American and Asia-Pacific regions to support surging demand for biosimilar characterisation and comparability testing. We are delighted to be working with more than 30 of the top biosimilar players globally and look forward to continued strong growth in 2014.”
BioOutsource Ltd, +44 141 946 4222, vmcerlane@biooutsource.com, www.biooutsource.com.